The Australian Advantage: Speed, Cost, Quality
Australia is a global powerhouse in life sciences, clinical research, and biotech innovation. With 5 of the world’s top 50 medical schools and more than 55 cutting-edge research institutes, it attracts a world-class network of medical experts and thought leaders driving the future of healthcare.
In the last two decades, Australia has become a preferred destination for early-phase clinical trials, thanks to a strong track record, global credibility, and streamlined processes.
Australia’s 50+ clinical trial networks, offer Phase 1 – 4 clinical trials headed by world-leading experts.
Backed by government and other sector investment, Australia provides specialised and dedicated infrastructure including globally highly regarded Phase 1 services.
With a favourable exchange rate and generous R&D tax incentives, running clinical trials in Australia can be up to 60% more cost effective than in the U.S.
In 2022 alone, $1.6 billion was invested in clinical trials, and Australia hosted 13% of all offshore trials globally, as reported by the Australian Clinical Trial Report/MTPConnect. The country’s infrastructure, expertise and cost advantages make it the go-to hub for international clinical research.
Why choose Australia?
Quality: Data Recognised by Global Regulatory Bodies
Quality is the one non-negotiable in this space. Australia is home to world-renowned institutes, expert researchers and state-of-the-art clinical trial facilities. This combination enables the generation of high-quality data that is recognised internationally and consistently used to support successful approvals from agencies like the FDA, EMA, PMDA, and Health Canada.
Speed: No IND required
Speed matters, and Australia delivers. Unlike the U.S., Australia doesn’t require an Investigational New Drug (IND) submission to begin Phase 1 trials. Instead, the streamlined ethics approval process takes just 4-6 weeks for healthy volunteer studies and approximately 12 weeks for patient studies. This speed advantage can potentially cut up to six months from a clinical trial timeline.
Cost: R&D Tax Incentives
Cost is another crucial advantage. With favourable exchange rates and substantial government incentives, including an R&D tax rebate of up to 43.5% for eligible companies, conducting clinical trials in Australia can be around 60% more cost-effective compared to the U.S.
You can find out more about the R&D tax incentive program through the Australian Government Business site here (https://business.gov.au/grants-and-programs/research-and-development-tax-incentive/overview-of-rd-tax-incentive).
In short, Australia is a winning choice—fast, efficient, cost-effective, and backed by world-class expertise. Ready to accelerate your clinical development?
360biolabs offers the guidance, support, and expertise needed to turn your clinical vision into reality.
Find more information on the Australian Advantage.
Chat to us about how we can accelerate your clinical development program.
Connect with us